New leader named for Infectious Disease Research Center

Raymond Goodrich
Raymond Goodrich

Written by Dallas Head

The Office of the Vice President for Research (OVPR) has selected Raymond Goodrich as the new Infectious Disease Research Center (IDRC) executive director. His appointment begins Oct. 1, 2016.

“We are excited to welcome Dr. Goodrich to lead our Infectious Disease Research Center,” said Alan Rudolph, vice president for research. “He brings unique translational research experience from the infectious disease industry – leading discoveries from the bench side to the market place.”

Goodrich will be the primary contact for all external and internal partners in infectious disease research. He will also manage relationships with external laboratories such as the U.S. Center for Disease Control and the National Wildlife Research Center.

In his new role, Goodrich will be in charge of strategic responsibility for the IDRC and will coordinate development and enhancement of infectious disease research and start-up companies. Part of the enhancement responsibilities of Goodrich will include oversight of infectious disease related startup companies and of BioMARC, an FDA-approved bio-manufacturing facility.

“We look forward to Dr. Goodrich’s leadership for our nationally recognized assets including CSU faculty, BioMarc, and start-ups,” Rudolph said.

Goodrich will also work toward lowering translational barriers for CSU researchers as well as managing the financial aspects, teaching and training for faculty in the IDRC.

About Raymond Goodrich

Goodrich has held positions in infectious disease research programs for the greater part of his career, specifically in transfusion medicine, translational research and infectious diseases. He is an active member of the American Chemical Society, the American Association of Blood Banks and the International Society of Blood Transfusion.

Most recently, Goodrich has been President of Innovata Bioconsulting, a consulting firm providing services to the medical device and pharmaceutical products sector. He was a founder of CryoPharm Corporation, a company focused on blood preservation and sterilization technologies.  He also formerly served as the Vice President of Clinical and Scientific Affairs and Chief Scientific Officer for the blood bank technologies division of Terumo BCT (previously known as Gambro BCT or CaridianBCT), a global leader in blood component and cellular technologies.

Goodrich has published over 200 peer reviewed scientific research articles and abstracts and is recognized as an international expert in transfusion and infectious disease pathogens. In addition, he has been awarded over 50patents covering methods and devices for cell separation, biological fluid sterilization and preparation of vaccines.

Goodrich received his Ph.D. in biophysical chemistry from the California Institute of Technology in Pasadena, California. He remains an adjunct professor of chemistry at The Ohio State University, and has lectured and taught for over 20 years.